home / stock / lbtsf / lbtsf news


LBTSF News and Press, Almirall Sa Ord From 07/26/21

Stock Information

Company Name: Almirall Sa Ord
Stock Symbol: LBTSF
Market: OTC

Menu

LBTSF LBTSF Quote LBTSF Short LBTSF News LBTSF Articles LBTSF Message Board
Get LBTSF Alerts

News, Short Squeeze, Breakout and More Instantly...

LBTSF - Almirall's (LBTSF) CEO Gianfranco Nazzi on Q2 2021 Results - Earnings Call Transcript

Almirall, S.A. (LBTSF) Q2 2021 Earnings Conference Call July 26, 2021 4:00 AM ET Company Participants Pablo Divasson – Head of Investor Relations Gianfranco Nazzi – Chief Executive Officer Karl Ziegelbauer – Chief Scientific Officer Mike McClellan – Chief Financial...

LBTSF - Almirall, S.A. 2021 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q2 earnings call. For further details see: Almirall, S.A. 2021 Q2 - Results - Earnings Call Presentation

LBTSF - Almirall, S.A. misses on revenue; updates full year guidance

Almirall, S.A. (LBTSF): 1H Normalised net income of €57.8MRevenue of €415.5M (-4.0% Y/Y) misses by $81.18M.The company is upgrading its Core EBITDA Guidance for 2021 to €195 MM - €215M (previously €190 MM-€210M)Press Release For further details see:...

LBTSF - Almirall delivers robust H1 performance and increases full-year guidance

Almirall delivers robust H1 performance and increases full-year guidance - Robust business performance with significant growth in Core EBITDA: Core Net Sales €415.5 MM (+8% year-on-year) and Core EBITDA reached €125.6 MM, (+40.4% year-on-year) - The company is ...

LBTSF - Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis

Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis - Klisyri® (tirbanibulin) is a topical first-in-class microtubule inhibitor indicated for the treatment of actinic keratosis (AK) of the fac...

LBTSF - Almirall receives positive CHMP opinion for Klisyri®? (tirbanibulin), an innovative topical treatment for actinic keratosis

Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or sca...

LBTSF - Almirall, S.A. 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Almirall, S.A. 2021 Q1 - Results - Earnings Call Presentation

LBTSF - Almirall SA (LBTSF) CEO Gianfranco Nazzi on Q1 2021 Results - Earnings Call Transcript

Almirall SA. (LBTSF) Q1 2021 Earnings Conference Call May 10, 2021, 04:00 AM ET Company Participants Pablo Divasson - Head, IR & CEC Jorge Ballart - Chairman, PD Carlos Gallardo - VC & PD Gianfranco Nazzi - CEO Michael McClellan - EVP, Finance & CFO Conference Call Participants Ja...

LBTSF - Almirall's solid core business Q1 performance boosted by Growth drivers momentum

Almirall's solid core business Q1 performance boosted by Growth drivers momentum - Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year) - Growth drivers momentu...

LBTSF - Almirall, S.A. reports FY results

Almirall, S.A. (LBTSF): FY normalized Net Income of €95.1MRevenue of €814.5M (-10.3% Y/Y)Press Release For further details see: Almirall, S.A. reports FY results

Previous 10 Next 10